Opioid drugs, including fentanyl, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for fentanyl, at any dose, and by any route of administration. Other opioids are considered in separate reviews.
use of rescue medication or intolerable adverse events ('responders'), were randomised to continue with fentanyl or switch to placebo for 12 weeks, under double-blind conditions. Our prespecified primary outcomes were not appropriate for this study design, but the measures reported do give an indication of the efficacy of fentanyl in this condition.
In the titration phase, 1 in 3 participants withdrew because of adverse events or inadequate pain relief, and almost 90% experienced adverse events. Of 258 participants who underwent open-label titration, 163 were 'responders' and entered the randomised withdrawal phase. The number of participants completing the study (and therefore continuing on treatment) without an increase of pain by more than 15/100 was 47/84 (56%) with fentanyl and 28/79 (35%) with placebo. Because only 63% responded sufficiently to enter the randomised withdrawal phase, this implies that only a maximum of 35% of participants entering the study would have had useful pain relief and tolerability with transdermal fentanyl, compared with 22% with placebo. Almost 60% of participants taking fentanyl were 'satisfied' and 'very satisfied' with their treatment at the end of the study, compared with about 40% with placebo. This outcome approximates to our primary outcome of moderate benefit using the Patient Global Impression of Change scale, but the group was enriched for responders and the method of analysis was not clear. The most common adverse events were constipation, nausea, somnolence, and dizziness.
There was no information about other types of neuropathic pain, other routes of administration, or comparisons with other treatments.
We downgraded the quality of the evidence to very low because there was only one study, with few participants and events, and there was no information about how data from people who withdrew were analysed.
Authors' conclusions
There is insufficient evidence to support or refute the suggestion that fentanyl works in any neuropathic pain condition.
P L A I N L A N G U A G E S U M M A R Y

Fentanyl for neuropathic pain in adults
Bottom line
There is no good evidence to support or refute the suggestion that fentanyl works in any neuropathic pain condition.
Background
Neuropathic pain is pain coming from a damaged nervous system. It is different from pain messages that are carried along healthy nerves from damaged tissue (e.g. from a fall or cut, or an arthritic knee). Neuropathic pain is often treated by different medicines (drugs) from those used for pain from damaged tissue, which we often think of as painkillers. There are different types of neuropathic pain, with different causes. Some medicines that are used to treat depression or epilepsy can be very effective in some people with neuropathic pain. Sometimes opioid painkillers are used to treat neuropathic pain.
Opioid painkillers are drugs such as morphine. Morphine is derived from plants, but many opioids are also made by chemical synthesis rather than being extracted from plants. Fentanyl is one of these synthetic opioids. It is available in numerous countries for use as a painkiller and, when used to treat chronic pain, is usually given through an adhesive patch, so it is taken into the body through the skin.
Study characteristics
In January 2016 we searched for clinical trials where fentanyl was used to treat neuropathic pain in adults. We found one small study that did this and met our requirements for the review. The study had a complicated design. Study participants first received fentanyl (as oneday skin patches) for one month. Those who responded to therapy (achieved a predetermined level of pain relief ) were then randomly allocated to continue receiving fentanyl or placebo for 12 weeks. The participants had one of three different types of neuropathic pain and had not taken opioids before. There were only 163 people in the 12-week comparison with placebo.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Transdermal fentanyl compared with placebo for neuropathic pain 
B A C K G R O U N D
This review is based on a template for reviews of drugs used to relieve neuropathic pain. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (Moore 2010a; Appendix 1).
Description of the condition
The 2011 International Association for the Study of Pain definition of neuropathic pain is "pain caused by a lesion or disease of the somatosensory system" (Jensen 2011), and is based on a definition agreed at an earlier consensus meeting (Treede 2008 
Description of the intervention
Fentanyl was first synthesised in the 1950s and was found to be significantly more potent than commonly used opioids, such as morphine. It was initially used for intravenous anaesthesia and analgesia in the 1960s and became a mainstay of intraoperative and perioperative analgesia and both conscious and deep sedation in the in-hospital setting. Peak analgesic effects of intravenous fentanyl last for 30 to 60 minutes, but onset of analgesia is rapid.
Fentanyl is approximately 80 to 100 times more potent than morphine, is highly lipophilic, and binds strongly to plasma proteins (Trescot 2008). Fentanyl is associated with possible hypoxaemia (low oxygen levels in the blood) after surgery (McQuay 1979) . Fentanyl undergoes extensive metabolism in the liver, and is subject to first-pass metabolism in the liver and possibly small intes-tine, though hepatic extraction from blood may be more complicated (Bullingham 1984) . Various formulations of fentanyl have been studied, including a rapid transmucosal formulation for buccal absorption or intranasal sprays for acute breakthrough pain, and transdermal formulations for chronic pain (Lötsch 2013; Nelson 2009 ). The transdermal formulation has a lag time of 6 to 12 hours to onset of action after application, and typically reaches steady state in three to six days. When a patch is removed, a subcutaneous reservoir remains, and drug clearance may take up to 24 hours. Fentanyl patches are available as generic formulations, and brand names include Fentalis ® , Matrifen ® , Mezolar ® , Osmanil ® , Tilofyl ® , Victanyl ® , Durogesic ® , and DTrans ® . They are available as 12, 25, 50, 75, and 100 µg/h transdermal patches. The 25, 50, 75, and 100 µg/h patches were first licensed in 1994, and a 12 µg patch followed in 2005. Transdermal fentanyl provides 'rate controlled' drug delivery over 72 hours, although shorter and longer delivery periods are under development. A 24-hour patch has been licensed for some pain conditions in Japan. Surface area exposed, skin permeability, and local blood flow determine absorption (Heiskanen 2009). Absorption was impaired in 10 cachectic (weak and underweight) compared with 10 normal weight cancer patients, (Heiskanen 2009). The 'reservoir patch' is being phased out and replaced with a matrix design, as it was likely to leak if damaged or cut. Trials have demonstrated no difference in pain intensity reduction or overall adverse effects between the reservoir and matrix patches. Satisfaction was improved, and wearability, adhesion, and comfort were improved with the matrix patches (Cachia 2011). Fentanyl patches have been suggested to have some benefits over more traditional opioids such as oral morphine. There is a favourable safety profile in people with renal insufficiency, as this does not affect fentanyl elimination, while renal insufficiency or failure cause a build-up of active metabolites of opioids such as morphine. Fentanyl is also considered to cause less constipation than morphine. However, fentanyl patches are not generally recommended in clinical practice for people who are opioid naïve. Moreover, exposure to heat through fever, sunbathing, hot showers or baths, and warm weather can cause more fentanyl to be released into the skin and cause serious, or even fatal, adverse events.
How the intervention might work
Opioids such as fentanyl bind to specific opioid receptors in the nervous system and other tissues; there are three principal classes of receptors (mu, kappa, and delta) though others have been suggested, and subtypes of receptors are considered to exist. Binding of opioid agonists such as fentanyl to receptors brings about complex cellular changes, the outcomes of which include decreased perception of pain, decreased reaction to pain, and increased pain tolerance. Opioids from plant sources have been used for thousands of years to treat pain.
Why it is important to do this review
One UK survey found that weak and strong opioids were used frequently for treating neuropathic pain (Hall 2013). Fentanyl patches can be useful in people who cannot tolerate oral opioids. Titrating the dose of fentanyl patches can be difficult and it is probably better to convert from a dose of morphine or other oral opioid that is effective but not tolerated. Since the early 2000s, a marked increase in prescribing of opioids for non-cancer pain in general, despite a relatively modest evidence base, has in some countries led to widespread diversion with consequent abuse, misuse, and mortality (Franklin 2014; Weisberg 2014; Zin 2014). There were 1.2 million prescriptions for fentanyl in primary care in England in 2014 at a cost of almost GBP57 million (PCA 2015) and the amount of fentanyl prescribed has been rising substantially (Zin 2014), although not all this prescribing will be for neuropathic pain.
Concurrently, suspicion has arisen that opioid-induced hyperalgesia, together with tolerance to the analgesic effects of opioids, may in reality result in a lesser degree of benefit for opioids in neuropathic pain than previously assumed. The standards used to assess evidence in chronic pain trials have evolved substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of 8 to 12 weeks' duration or longer. A pain intensity reduction of 50% or more correlates with improvements in comorbid symptoms, function, and quality of life. These standards are set out in the Cochrane Pain, Palliative and Supportive Care Group (PaPaS) Author and Referee Guidance for pain studies (PaPaS 2012). This Cochrane review assessed evidence using methods that make both statistical and clinical sense, and used developing criteria for what constitutes reliable evidence in chronic pain (Moore 2010a). To be included, trials had to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc.), and size (ideally at least 500 participants in a comparison in which the NNT is 4 or above; Moore 1998). This approach sets high standards for the demonstration of efficacy and marks a departure from how reviews were conducted previously.
Taking this newer, more rigorous approach is particularly important for opioids in chronic non-cancer pain. Opioids in clinical trials in non-cancer pain are associated with very high withdrawal rates of up to 60% over about 12 weeks (Moore 2010b). Many withdrawals occur within the first few weeks, when participants experience pain relief but cannot tolerate the drug. The common practice of using the last observed results carried forward to the end of the trial many weeks later (last observation carried forward (LOCF)) can, therefore, produce results based largely on people who are no longer in the trial, and who in the real world could not achieve pain relief because they could not take the tablets. The newer standards, outlined in Appendix 1, would not allow this and can produce very different results. For example, one large analysis of pooled data from trials in osteoarthritis and chronic low back pain conducted over about 12 weeks judged oxycodone effective, but an analysis of the same data using the new clinically meaningful standards showed it to be significantly worse than placebo (Lange 2010). One previous Cochrane review demonstrated the limitations of our knowledge about opioids in neuropathic pain except in short duration studies of 24 hours or less (McNicol 2013). These limitations were confirmed by reviews specific to buprenorphine and oxycodone (Gaskell 2014; Wiffen 2015) . A review specific to fentanyl is timely.
O B J E C T I V E S
To assess the analgesic efficacy of fentanyl for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials with double-blind assessment of participant outcomes following two weeks or more of treatment, although the emphasis of the review was on studies with a duration of eight weeks or longer. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were non-randomised, studies of experimental pain, case reports, and clinical observations.
Types of participants
We included studies involving adults aged 18 years and above with one or more chronic neuropathic pain condition including (but not limited to): 1. cancer-related neuropathy; 2. central neuropathic pain; 3. complex regional pain syndrome (CRPS) Type II; 4. human immunodeficiency virus (HIV) neuropathy; 5. painful diabetic neuropathy (PDN); 6. phantom limb pain; 7. postherpetic neuralgia (PHN); 8. postoperative or traumatic neuropathic pain; 9. spinal cord injury; 10. trigeminal neuralgia. Where studies included participants with more than one type of neuropathic pain, we planned to analyse results according to the primary condition.
Types of interventions
Fentanyl at any dose, by any route, administered for the relief of neuropathic pain and compared with placebo or any active comparator.
Types of outcome measures
We anticipated that studies would use a variety of outcome measures, with most studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity (where higher numbers indicate more pain) or pain relief (where higher numbers indicate more relief ), or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (Dworkin 2008) . These are defined as:
1. at least 30% pain relief over baseline (moderate benefit); 2. at least 50% pain relief over baseline (substantial benefit); 3. much or very much improved on Patient Global Impression of Change scale (PGIC; moderate benefit); and 4. very much improved on PGIC (substantial benefit). These outcomes are different from those used in most earlier reviews, concentrating as they do on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50% pain intensity reduction, and ideally having no worse than mild pain (Moore 2013a; O'Brien 2010). We have included a 'Summary of findings' table as set out in the PaPaS author guide (PaPaS 2012), to include outcomes of at least 30% and at least 50% pain intensity reduction, much or very much improvement on PGIC, withdrawals due to adverse events, serious adverse events, and death. We used the GRADE approach to assess the quality of evidence related to each of the key outcomes listed below (Chapter 12, Higgins 2011), as appropriate.
Secondary outcomes
1. Any pain-related outcome indicating some improvement 2. Withdrawals due to lack of efficacy, adverse events, and for any cause 3. Participants experiencing any adverse event 4. Participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is lifethreatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the person, or may require an intervention to prevent one of the above characteristics or consequences 5. Specific adverse events, particularly somnolence and dizziness
Search methods for identification of studies
Electronic searches
We searched the following databases, without language restrictions. 
Searching other resources
We reviewed the bibliographies of relevant studies and review articles, and searched two clinical trial registries, (ClinicalTrials.gov (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (apps.who.int/ trialsearch/)), to identify additional published or unpublished data. We contacted Janssen-Cilag Ltd who were able to clarify the publication status of the included study shortly before full publication. We did not contact investigators or other study sponsors.
Data collection and analysis
We planned to perform separate analyses according to particular neuropathic pain conditions, combining different neuropathic pain conditions in analyses for exploratory purposes only.
Selection of studies
We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors made the decisions, reading these studies independently and reaching agreement by discussion. We did not anonymise the studies in any way before assessment. We have included a PRISMA flow chart (Figure 1 ).
Figure 1. Study flow diagram.
Data extraction and management
Two review authors extracted data independently using a standard form and checked for agreement before entry into Review Manager 5 (RevMan 2014) or any other analysis tool. We included information about the pain condition and number of participants treated, drug and dosing regimen, control intervention, study design, study duration and follow up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event or serious adverse event).
Assessment of risk of bias in included studies
We used the Oxford Quality Score as the basis for inclusion (Jadad 1996) , limiting inclusion to studies that were randomised and double-blind as a minimum. Two review authors independently assessed the risk of bias for each study, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Chapter 8, Higgins 2011), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study. 1. Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, random number table, computer random number generator); unclear risk of bias (when the method used to generate the sequence is not clearly stated). We excluded studies at a high risk of bias that used a non-random process (odd or even date of birth, hospital or clinic record number).
2. Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation, consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when method was not clearly stated). We excluded studies that did not conceal allocation and were, therefore, at a high risk of bias (open list).
3. Blinding of outcome assessment (checking for possible detection bias). We planned to assess the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, identical tablets, matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies at a high risk of bias that were not double-blind. 4. Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (fewer than 10% of participants did not complete the study, or used 'baseline observation carried forward' analysis (BOCF), or both); unclear risk of bias (used LOCF analysis); or high risk of bias (used 'completer' analysis).
5. Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate NNTs as the reciprocal of the absolute risk reduction (McQuay 1998) . For unwanted effects, the NNT becomes the number needed to treat for an additional harmful outcome (NNH) and is calculated in the same manner. We planned to use dichotomous data to calculate risk ratios (RRs) with 95% confidence intervals (CIs) using a fixed-effect model unless we found significant statistical heterogeneity (see Assessment of heterogeneity). We planned not to use continuous data in analyses, and intended to extract and use continuous data, which probably reflect efficacy and utility poorly, only if useful for illustrative purposes.
Unit of analysis issues
We accepted randomisation to the individual participant only. We planned to split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis.
Dealing with missing data
We planned to use intention-to-treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post-baseline assessment. We would assign zero improvement to missing participants wherever possible.
Assessment of heterogeneity
We planned to deal with clinical heterogeneity by combining studies that examined similar conditions, and to assess statistical heterogeneity visually (L'Abbé 1987) and with the use of the I 2 statis-tic. When the I 2 value was greater than 50%, we would consider possible reasons for this.
Assessment of reporting biases
The aim of this review was to use dichotomous outcomes of known utility and of value to patients with pain (Hoffman 2010; Moore 2010c; Moore 2010d; Moore 2010e; Moore 2013a). The review would not depend on what the authors of the original studies chose to report or not, though clearly difficulties would arise in studies that did not report any dichotomous results. We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher; Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We would have used a random-effects model for meta-analysis if there was significant clinical heterogeneity and it was considered appropriate to combine studies. We planned to analyse data for each painful condition separately.
Quality of the evidence
We used the GRADE system to assess the quality of the evidence related to the key outcomes listed in Types of outcome measures, as appropriate (Appendix 5; Chapter 12.2, Higgins 2011). Two review authors independently rated the quality of evidence for each outcome. We paid particular attention to:
1. inconsistency, where point estimates vary widely across studies, or CIs of studies show minimal or no overlap (Guyatt 2011); 2. potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (Moore 2008 ). In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (Guyatt 2013a). For example, if there are so few data that the results are highly susceptible to the random play of chance, or if a study used LOCF imputation in circumstances where there are substantial differences in adverse event withdrawals, one would have no confidence in the result and would need to downgrade the quality of the evidence by three levels to very low quality. In circumstances where no data were reported for an outcome, we would report the level of evidence as very low quality (Guyatt 2013b).
'Summary of findings' table
We have included a 'Summary of findings' table to present the main findings in a transparent and simple tabular format. In particular, we have included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes of 'moderate' and 'substantial' benefit, withdrawal due to lack of efficacy, withdrawal due to adverse events, serious adverse events, and death.
Subgroup analysis and investigation of heterogeneity
We planned all analyses to be according to individual neuropathic pain conditions, because placebo response rates for the same outcome can vary between conditions, as can the drug-specific effects (Moore 2009 ). We did not plan subgroup analyses since our experience of previous reviews indicates that there would be too few data for any meaningful subgroup analysis (Gaskell 2014; McNicol 2013) .
Sensitivity analysis
We planned no sensitivity analysis because the evidence base was known to be too small to allow reliable analysis. We planned to examine details of dose-escalation schedules in the unlikely situation that this could provide some basis for a sensitivity analysis, but this was not possible.
R E S U L T S
Description of studies
Results of the search
Searches identified 193 potentially relevant records in CENTRAL, 452 in MEDLINE, and 770 in Embase, and two in clinical trial registries. After deduplication and reading the titles and abstracts we obtained and read the full texts of five published records and two clinical trial registry reports. We excluded five studies, and included one (two reports) (Figure 1) .
Included studies
We included one study, identified as a registry report (NCT01008553) and in a published pooled analysis (Arai 2015) . This study used an enriched enrolment randomised withdrawal (EERW) design in which 258 participants underwent open-label titration over 10 to 29 days with fentanyl one-day patches to determine the maximum tolerated dose. It was not clear whether participants stopped or continued with previously inadequate medication.
Those who had pain intensity below 45/100 in the last three days of this open-label titration, an improvement from pre-treatment of at least 15/100, achieved a stable dosage of fentanyl, and required fewer than two doses per day of rescue medication, were classified as 'responders' (163 participants; 63% of those entering the open titration period) and were randomised to double-blind treatment with either the same dose of fentanyl or placebo for 12 weeks. Of 84 receiving fentanyl, 47 completed the 12 weeks, compared with 28/79 receiving placebo (Arai 2015). Fentanyl was administered as a one-day patch, and all participants started with fentanyl 12.5 µg/h, increasing to a maximum of 50 µg/h over 10 to 29 days. Morphine hydrochloride was available as rescue medication (5 mg per fentanyl 12.5 µg/h). Participants were opioid-naïve and had pain that was not adequately controlled with non-opioid analgesics. They were adults (mean age 67 years) with PHN (51%), CRPS (type not specified, 20%), or chronic postoperative pain (for a duration of 12 weeks or more, but no further details given; 29%). There were approximately equal numbers of men and women. Mean baseline pain intensity was 74/100 before treatment and 40/100 at the end of titration. For those entering the double-blind period, baseline pain was 30/100 in the fentanyl group and 28/100 in the placebo group.
Excluded studies
We excluded five studies. Three were open-label studies, two of which were in mixed pain conditions, one was a single-blind study (ongoing), and one compared fentanyl with fentanyl plus gabapentin (no appropriate control). See the Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 2 for a summary of our assessment of the risk of bias in the included study. Studies with EERW designs are likely to have additional sources of bias, or may require somewhat different assessments (Moore 2015), but we have not included those here.
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included
study.
Allocation
The study did not report the methods used to generate the randomisation sequence or to conceal allocation (unclear risk of bias).
Blinding
Blinding was achieved by using a placebo patch that was indistinguishable from the fentanyl patch. There was a period of downtitration for the placebo group, which would help to maintain the blinding (low risk of bias).
Incomplete outcome data
Study did not mention how missing data were handled. The study's primary outcome (median time to withdrawal) appears robust, but other outcomes are unclear.
Other potential sources of bias
We judged the study to be at unclear risk of bias due to its size (84 and 79 participants in treatment arms for the randomised phase).
Effects of interventions
See: Summary of findings for the main comparison
Since we identified only one study for inclusion, we were unable to carry out any analyses.
Efficacy
Details of efficacy outcomes are provided in Appendix 6.
Participants with at least 30% or at least 50% pain relief
These outcomes were not reported.
PGIC much or very much improved
The study reported the participants' assessment of 'treatment satisfaction for pain' on a five-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, very satisfied) after the double-blind phase. We judged that the categories of 'satisfied' and 'very satisfied' approximate to our PGIC outcome of moderate benefit. In the fentanyl group, 49/84 (58%) participants were either satisfied or very satisfied, and corresponding data in the placebo group were 32/79 (41%). It is not clear how data from participants who withdrew due to adverse events were analysed for this outcome, but some form of imputation must have been used for participants who withdrew as the numbers are greater than the number who completed the study.
Other pain-related outcomes
The primary outcome chosen in the study was median time to withdrawal from the double-blind phase, where withdrawal occurred when there was worsening of pain of 15/100 (mean increase over three consecutive days) from entry into this phase, use of three or more doses of rescue medication per day for five or more days, the participant requested it because of a lack of efficacy, or the participant requested an increase in study drug dosage. The median time to withdrawal for the placebo group was 45 days, but could not be estimated for the fentanyl group because fewer than half the participants withdrew over the 12 weeks; the assumption must be that the median time to withdrawal was greater than 42 days.
The study did not report the number of participants who remained 'responders' at the end of the 12-week double-blind treatment period as a treatment outcome. However, Arai 2015 reports the number of participants completing the study (and therefore continuing on treatment) without an increase in pain of more than 15/100. For fentanyl, this was 47/84 (56%) and for placebo it was 28/79 (35%). The implication, then, is that because only 63% responded sufficiently to enter the randomised withdrawal phase, only a maximum of 35% of participants entering the study would have useful pain relief and tolerability with transdermal fentanyl, compared with 22% with placebo. The group mean change (increase) in pain intensity from randomisation to the end of the double-blind phase (mean of last three days) was 0.5/100 (from 30.1 to 29.6) in the fentanyl group, and 9.6/100 (from 27.5 to 37.1) in the placebo group. This mean change is unlikely to be of clinical significance, but probably masks larger changes in some individuals. It is not clear how data from participants who withdrew during treatment were analysed for this outcome.
We downgraded the quality of the evidence for efficacy to very low because there was only one study, with a small number of participants, low numbers of events, and there was no information about how participants who withdrew from the study were analysed (see Summary of findings for the main comparison).
Withdrawals
Details of withdrawals are provided in Appendix 7.
Withdrawals due to lack of efficacy
Following the titration period, 50/258 participants were classified as non-responders to fentanyl. During the double-blind period, one participant taking fentanyl withdrew because of perceived lack of efficacy, and a further 18/84 were withdrawn because they experienced a greater than 15/100 increase in pain intensity. With placebo, 4/79 withdrew because of perceived lack of efficacy, and a further 35/79 were withdrawn because they experienced a greater than 15/100 increase in pain intensity.
Withdrawals due to adverse events
During titration 39/258 participants withdrew due to adverse events. During the double-blind period 14/84 participants taking fentanyl and 4/79 taking placebo withdrew due to adverse events.
Other withdrawals
During titration 12/258 participants withdrew because of physician (2) or participant (6) decision, participant was determined to increase dosage (3), and participant was considered not appropriate for the study (1). During the double-blind period 4/84 participants taking fentanyl withdrew due to physician (1) or participant (2) decision, and an inability to perform required tests (1), and 8/79 taking placebo withdrew due to physician (2) or participant (2) decision, and excessive use of rescue medication (4).
We downgraded the quality of the evidence for withdrawals to very low because there was only one study, with a small number of participants per treatment arm in the randomised withdrawal phase, and low numbers of events.
Adverse events
Details of adverse events are provided in Appendix 7.
Any adverse event
During the titration phase, 231/258 (90%) participants experienced at least one adverse event. During the double-blind phase, 72/84 (86%) and 56/79 (71%) participants experienced at least one adverse event with fentanyl and placebo, respectively. Generally, participants experienced fewer adverse events during the double-blind period. Most adverse events were of mild or moderate intensity.
Serious adverse events
During the titration phase, 13/258 participants experienced a serious adverse event. During the double-blind phase, 8/84 and 4/79 participants experienced a serious adverse event with fentanyl and placebo, respectively. No serious adverse event occurred in more than one participant, and no deaths were reported.
Specific adverse events
Constipation (124/258), nausea (103/258), somnolence (118/ 258), and dizziness (52/258) were the most common adverse events reported during the titration period. As would be expected, the rates of these events were lower in the double-blind period. Among the 84 participants taking fentanyl in the double-blind phase, 12 reported constipation, 12 nausea, 12 somnolence, and 6 dizziness, and among 79 taking placebo, 10 reported constipation, 10 nausea, 5 somnolence, and 3 dizziness. A small number of participants experienced application-site reactions during titration: pruritus (15/258), erythema (8/258), dermatitis (4/258), rash (3/258). Few participants in either group reported these events during the double-blind period.
We downgraded the quality of the evidence for adverse events to very low because there was only one study, with a small number of participants per treatment arm in the randomised withdrawal phase, and low numbers of events.
D I S C U S S I O N
Summary of main results
We found only one study to include in this review. The study assessed the efficacy of fentanyl, using the transdermal route of administration, for the treatment of neuropathic pain in opioidnaïve participants; 258 participants entered the dose-titration period, and 163 'responders' entered the double-blind phase. The results indicated a reduction in pain intensity with open-label fentanyl that was better maintained with fentanyl than placebo in the randomised, double-blind withdrawal period. However, during titration, 1 in 3 (101/258) participants withdrew overall, mainly due to intolerable adverse events (1 in 7; 39/258) or not achieving a sufficiently good level of pain relief to proceed to the doubleblind phase (1 in 5; 50/258). Of those who did enter the doubleblind phase, only about 1 in 2 (37/84) in the fentanyl group and 2 in 3 (51/79) in the placebo group maintained good pain relief and were able to tolerate adverse events over 12 weeks.
Taking the pool of participants originally recruited, therefore, after 12 weeks treatment a maximum of about 3 in 10 would have maintained low pain and continued with the treatment, compared with 2 in 10 with placebo. Most (90%) participants experienced adverse events during the titration phase, and the majority continued to do so in the doubleblind phase, although most participants experienced fewer events. Most adverse events were of mild or moderate intensity, and the most common were constipation, nausea, somnolence, and dizziness, which are typically associated with opioids.
Overall completeness and applicability of evidence
The amount of evidence we have is small, from a single study. Although participants had three different types of neuropathic pain, the study was underpowered to demonstrate a differential response. Participants were opioid-naïve at screening, so high numbers of adverse events and withdrawals are to be expected; lower levels might be seen in an unselected or opioid-tolerant population. Fentanyl patches are generally not recommended for opioidnaïve patients. About half of participants had PHN, 20% had CRPS, and 29% had chronic postoperative pain at enrolment. The study did not specify CRPS type II as an inclusion criterion, and provided no further details about the nature of the surgery leading to postoperative pain. We have no information about the efficacy of fentanyl in other types of neuropathic pain, such as diabetic neuropathy, or about routes of administration other than transdermal, or comparisons with other active treatments. The particular formulation used in this study is not commonly used; in most countries a 72hour (three-day) patch is available. As best we know, there is insufficient evidence to support or refute the use of fentanyl for treating neuropathic pain. This is despite the fact that a UK survey found that weak and strong opioids were used frequently for treating neuropathic pain, either alone or in combination with other drugs (Hall 2013). The lack of evidence for long-term benefit with fentanyl reflects similar findings for oxycodone, buprenorphine, and other opioids (Gaskell 2014; McNicol 2013; Wiffen 2015) . This lack of evidence of efficacy combined with substantial evidence of harm has led to calls for referral to a pain management specialist (ideally with expertise in opioid use) if daily dosing exceeds 80 to 100 mg morphine equivalents, particularly if pain and function are not substantially improved (Franklin 2014).
The number of participants in the single included study (258 screened, 163 in the randomised double-blind phase) contrasts with 1096 who participated in randomised open studies and 1393 in observational studies of various designs (Appendix 8). Despite there being 2489 participants in these studies, with chronic pain of mostly mixed origins, no useful conclusions can be drawn because of problems in design, in outcomes, and in comparators used. Although some people had useful pain relief with fentanyl, there is no additional evidence that the proportion would be any higher than with no treatment.
One study did provide a useful insight into the relative efficacy of transdermal fentanyl and oral pregabalin in neuropathic cancer pain (Raptis 2014). The study had a randomised but open parallel design and was conducted over four weeks with initial titration for both drugs; initial pain relief was high, about 7/10 on a numerical rating scale. Of 60 participants given transdermal fentanyl, 22 (37%) had pain intensity reduction of 30% or more. Of 60 participants given oral pregabalin, 44 (73%) had that degree of pain reduction. All-cause withdrawals were 10/60 for fentanyl and 3/ 60 for pregabalin. Pregabalin has a well-established evidence base in neuropathic pain (Moore 2009 ), and the evidence from this open, but otherwise well-conducted study, indicates fentanyl to be much less effective.
Quality of the evidence
The methods used in the included study are fundamentally sound, but the study is substantially underpowered, particularly for the randomised, double-blind, withdrawal phase, and does not specify the imputation method(s) used for withdrawals . It does not report the most useful outcome from the double-blind phase, the number of participants who maintained therapeutic efficacy and were able to continue taking the medication (with tolerable adverse events), although we were able to estimate this. These factors downgrade the evidence for all outcomes to very low quality, which means that further research is very likely to have an important impact on our confidence in our understanding of the effect.
Potential biases in the review process
We know of no potential biases in the review process. It is unlikely that there is a large body of unpublished evidence showing a large effect from fentanyl in neuropathic pain.
Agreements and disagreements with other studies or reviews
This review agrees with previous reviews and Cochrane reviews that there appears to be no body of good clinical studies assessing the efficacy of fentanyl, at any dose or in formulation, for neuropathic pain (McNicol 2013) . The one study in this review was published after McNicol 2013. A recent review of all pharmacotherapy for neuropathic pain in adults did not mention fentanyl (Finnerup 2015) .
A U T H O R S ' C O N C L U S I O N S
Implications for practice For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion that fentanyl has any efficacy in any neuropathic pain condition.
For clinicians
For policy makers
In the absence of any supporting evidence, it should probably not be recommended, except at the discretion of a pain specialist with particular expertise in opioid use.
For funders
Implications for research
Large, robust, randomised trials with patient-centred outcomes would be required to produce evidence to support or refute the efficacy of fentanyl in neuropathic pain. The necessary design of such trials is well established, but, for opioids in neuropathic pain, the main outcomes should be those of at least a 30% and at least a 50% reduction in pain intensity over baseline at the end of a trial of 12 weeks' duration in participants continuing on treatment.
Withdrawal for any reason should be regarded as treatment failure, and LOCF analysis should not be used. The reason for this is that, in chronic pain, opioids frequently produce withdrawal rates of 50% or more, meaning that LOCF analysis can overstate treatment efficacy to a large extent. BOCF should be used in preference to LOCF as it provides a more relevant estimate of efficacy for the real world.
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